The US FDA’s priority level for redaction and posting of biosimilar reviews may be hard to square with its approach to the follow-on products’ labeling and the agency's view of their potential to reduce drug prices.
Between March 2015 and July 2018, FDA licensed 12 biosimilars. However, action packages, which include various discipline reviews and other materials, have been posted for only the first four approvals...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?